TY  - GEN
AU  - Vesole,David H
AU  - Bilotti,Elizabeth
AU  - Richter,Joshua R
AU  - McNeill,Ann
AU  - McBride,Laura
AU  - Raucci,Laura
AU  - Anand,Palka
AU  - Bednarz,Urszula
AU  - Ivanovski,Kristin
AU  - Smith,Judith
AU  - Batra,Veena
AU  - Aleman,Adolfo
AU  - Sims,Taliah
AU  - Guerrero,Laura
AU  - Mato,Anthony
AU  - Siegel,David S
TI  - Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
SN  - 1365-2141
PY  - 2015///1204
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Dexamethasone
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Hydroxamic Acids
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Oligopeptides
KW  - Survival Rate
KW  - Thalidomide
KW  - Vorinostat
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/bjh.13517
ER  -